Scarica l'app Stockscreener
38.36
2.32%
0.87
Pre-mercato:
37.88
-0.48
-1.25%
Precedente Chiudi:
$37.49
Aprire:
$37.53
Volume 24 ore:
33,519
Relative Volume:
0.70
Capitalizzazione di mercato:
$234.48M
Reddito:
-
Utile/perdita netta:
$-7.12M
Rapporto P/E:
-16.68
EPS:
-2.3
Flusso di cassa netto:
$-6.82M
1 W Prestazione:
+32.64%
1M Prestazione:
+28.94%
6M Prestazione:
+644.85%
1 anno Prestazione:
+4,981%
Intervallo 1D:
$35.21
$40.90
Intervallo di 1 settimana:
$26.05
$40.90
Portata 52W:
$0.3438
$54.30
Monopar Therapeutics Inc Stock (MNPR) Company Profile
Nome
Monopar Therapeutics Inc
Settore
Industria
Telefono
(847) 388-0349
Indirizzo
1000 SKOKIE BLVD SUITE 350, WILMETTE
Confronta MNPR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
38.36 | 234.48M | 0 | -7.12M | -6.82M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.49 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.91 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
605.38 | 36.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
230.93 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.84 | 25.73B | 3.81B | -644.79M | -669.77M | -6.24 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-19 | Ripresa | Piper Sandler | Overweight |
| 2025-01-10 | Iniziato | Piper Sandler | Overweight |
| 2024-10-11 | Iniziato | Rodman & Renshaw | Buy |
| 2021-01-28 | Iniziato | ROTH Capital | Buy |
Monopar Therapeutics Inc Borsa (MNPR) Ultime notizie
Monopar Therapeutics Inc. acquired worldwide license to ALXN-18 from Alexion Pharmaceuticals, Inc. for approximately $110 million. - MarketScreener
(MNPR) Long Term Investment Analysis - news.stocktradersdaily.com
Major Shareholder Sells Big Chunk of Monopar Therapeutics Stock! - TipRanks
Monopar Therapeutics CEO Robinson sells $1.17 million in stock By Investing.com - Investing.com Canada
Monopar Therapeutics CEO Robinson sells $1.17 million in stock - Investing.com
Jones Trading Reiterates “Hold” Rating for Monopar Therapeutics (NASDAQ:MNPR) - Defense World
HC Wainwright Issues Negative Forecast for MNPR Earnings - Defense World
What is HC Wainwright’s Forecast for MNPR FY2029 Earnings? - Defense World
Monopar Therapeutics downgraded to Hold from Buy at JonesResearch - TipRanks
We Think Monopar Therapeutics (NASDAQ:MNPR) Can Easily Afford To Drive Business Growth - Yahoo Finance
Monopar Therapeutics (NASDAQ:MNPR) Receives “Buy” Rating from HC Wainwright - Defense World
Top 5 Small-cap Biotech Stocks of 2025 - Nasdaq
Monopar Therapeutics Stock Hits 52-Week High at $38.91 - MSN
Monopar Therapeutics Inc: Strategic Advancements and Promising Financial Projections Justify Buy Rating - TipRanks
Buy Rating for Monopar Therapeutics Inc: Strategic Advancements and Promising Financial Outlook - TipRanks
Monopar Therapeutics reports Q4 EPS ($2.23) vs. (60c) last year - TipRanks
Monopar Therapeutics sees cash runway through December 31, 2026 - TipRanks
Monopar Therapeutics Inc. (MNPR) reports earnings - Quartz
Monopar Therapeutics SEC 10-K Report - TradingView
Monopar Secures 2-Year Runway with $60M War Chest, Advances Wilson Disease Drug - Stock Titan
MNPR Stock Price and Chart — NASDAQ:MNPR - TradingView
Here's Why Momentum in Monopar Therapeutics (MNPR) Should Keep going - Yahoo Finance
Piper Sandler Reaffirms “Overweight” Rating for Monopar Therapeutics (NASDAQ:MNPR) - Defense World
Monopar Therapeutics (MNPR) to Release Quarterly Earnings on Thursday - Defense World
Monopar a new overweight at Piper Sandler on rare disease asset - Seeking Alpha
Piper Sandler sets Monopar stock at $76 with Overweight rating - Investing.com
Buy Rating for Monopar Therapeutics Inc. Driven by Strategic Acquisition and ALXN1840 Potential - TipRanks
Piper Sandler sets Monopar stock at $76 with Overweight rating By Investing.com - Investing.com UK
(MNPR) Trading Report - news.stocktradersdaily.com
Monopar Therapeutics Inc.'s (NASDAQ:MNPR) 19% loss last week hit both individual investors who own 33% as well as institutions - Simply Wall St
Monopar Therapeutics: Strong Data, But There Are Risks (NASDAQ:MNPR) - Seeking Alpha
Monopar Therapeutics appoints new CFO - Investing.com
Monopar Therapeutics Appoints Quan Vu as New CFO - TipRanks
Monopar Therapeutics Inc Says On Feb 28, CFO Karthik Radhakrishnan'S Employment Terminated - Marketscreener.com
Monopar Therapeutics appoints new CFO By Investing.com - Investing.com Australia
Monopar Therapeutics appoints new board member - Investing.com
Monopar Therapeutics appoints new board member By Investing.com - Investing.com UK
Monopar Therapeutics Appoints Lavina Talukdar to Board - TipRanks
Trend Tracker for (MNPR) - Stock Traders Daily
Copper wired: Monopar to electrify Wilson disease? - BioWorld Online
Q1 EPS Estimate for Monopar Therapeutics Raised by Analyst - MarketBeat
Learn to Evaluate (MNPR) using the Charts - Stock Traders Daily
Brookline Capital Management Forecasts MNPR Q1 Earnings - Defense World
Monopar's Incredible Journey From $5 To $50 In Less Than 5 Months - RTTNews
Why Monopar Therapeutics Inc (MNPR) Is Skyrocketing So Far In 2025 - MSN
Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025 - Insider Monkey
What's Going On With Cancer-Focused Monopar Therapeutics Stock Today? - MSN
What is HC Wainwright’s Forecast for MNPR FY2026 Earnings? - Defense World
Analysts Set Expectations for MNPR FY2029 Earnings - MarketBeat
Monopar Therapeutics Inc Azioni (MNPR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.98%
5.78%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):